Biophytis raises €5.3M to fund obesity drug trial
What's the deal? BiophytisDealroom has a profile for this one. Try Dealroom → has completed a €5.3 million capital increase to fund a Phase 2 clinical trial targeting obesity. The raise, backed by European and US institutional investors, came through the issuance of over 101 million new shares and associated warrants.
What's the endgame? The trial will test Biophytis' BIO101 drug as an add-on to existing GLP-1 receptor therapies, with a focus on preserving muscle strength during weight loss. The study is set to launch in Q1 2027, with first results expected in the first half of 2028.
What's the money for? The funds will primarily drive the trial across the US, EU, and Brazil while sustaining operations into Q1 2028. Proceeds also cover part of Biophytis' remaining debt to HexagonDealroom has a profile for this one. Try Dealroom →, reducing the outstanding balance.
Why now? The raise secures the trial's runway to mid-2028. It marks a step up from the company's previous financing.
The signal: GLP-1 weight-loss drugs have reshaped the obesity market, but muscle loss during rapid weight reduction remains a concern. Biophytis is positioning BIO101 to fill that gap as a complementary therapy.
Read more: webdisclosure.com
Image credit: Generated with Gemini
